{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:54:37Z","timestamp":1790801677851,"version":"4.1.0"},"reference-count":11,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T00:00:00Z","timestamp":1599436800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Respiratory J"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Fluoroquinolone antibiotics, namely ciprofloxacin and levofloxacin, play an important role in treating infection in cystic fibrosis (CF) and ciprofloxacin remains the last widely used and orally available antipseudomonal agent. Recently, a new fluoroquinolone, delafloxacin, has been approved by the FDA for the indication of Acute Bacterial Skin and Skin Structure Infections (ABSSSI). This antibiotic is a novel dual\u2010targeting anionic fluoroquinolone and differs from previous agents in its class, as it lacks a protonatable substituent. To date, there are no reports of its use or activity against\n                      <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                      in CF. Alarmingly, fluoroquinolone resistance is increasing among CF\n                      <jats:italic>P aeruginosa<\/jats:italic>\n                      isolates. The aims of the study were to (a) examine in vitro susceptibility of delafloxacin against a population of\n                      <jats:italic>P. aeruginosa<\/jats:italic>\n                      (n\u00a0=\u00a052) isolated from adult CF patients at our CF centre, (b) to compare delafloxacin and ciprofloxacin in vitro susceptibilities against CF\n                      <jats:italic>P. aeruginosa<\/jats:italic>\n                      and (c) to evaluate where delafloxacin may add benefit in treating CF\n                      <jats:italic>P aeruginosa<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In vitro susceptibilities were examined on 52 non\u2010mucoid\n                      <jats:italic>P. aeruginosa<\/jats:italic>\n                      and\n                      <jats:italic>P. aeruginosa<\/jats:italic>\n                      ATCC\u2122 27853 reference strain, by employing Etest\n                      <jats:sup>\u00ae<\/jats:sup>\n                      gradient test strips for delafloxacin (range:0.002 \u2010 32\u00a0mg\/L) and ciprofloxacin (0.002 \u2010 32\u00a0mg\/L), as per manufacturer's instructions (Biomerieux).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      MIC range, MIC\n                      <jats:sub>50<\/jats:sub>\n                      and MIC\n                      <jats:sub>90<\/jats:sub>\n                      for delafloxacin were 0.064\u00a0\u2192\u00a032\u00a0mg\/L, 0.56\u00a0mg\/L and 2.19\u00a0mg\/L, respectively. For ciprofloxacin, these were 0.047\u00a0\u2192\u00a032\u00a0mg\/L, 1.69\u00a0mg\/L and 8.0\u00a0mg\/L, respectively. Overall, isolates were statistically more sensitive to delafloxacin (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.0005) than ciprofloxacin. Of note, 4\/12 (33.3%) isolates with intermediate resistance to ciprofloxacin were sensitive to delafloxacin. Similarly, 10\/28 (35.7%) isolates resistant to ciprofloxacin were sensitive to delafloxacin, with only 17.9% isolates resistant to ciprofloxacin, resistant to delafloxacin.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Given similar breakpoints of these fluoroquinolones, these data show that delafloxacin has greater activity than ciprofloxacin. While delafloxacin and ciprofloxacin were equally effective with sensitive isolates, the value of delafloxacin was noted with more resistant isolates to ciprofloxacin. While ciprofloxacin should remain the first line fluoroquinolone for treating CF\n                      <jats:italic>P aeruginosa<\/jats:italic>\n                      , delafloxacin shows potential in treating ciprofloxacin\u2010resistant\n                      <jats:italic>P aeruginosa<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/crj.13262","type":"journal-article","created":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T17:49:18Z","timestamp":1597340958000},"page":"116-120","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Delafloxacin\u2013\u2013A novel fluoroquinolone for the treatment of ciprofloxacin\u2010resistant\n                    <i>Pseudomonas aeruginosa<\/i>\n                    in patients with cystic fibrosis"],"prefix":"10.1111","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0745-8722","authenticated-orcid":false,"given":"Beverley Cherie","family":"Millar","sequence":"first","affiliation":[{"name":"Department of Bacteriology Northern Ireland Public Health Laboratory Belfast City Hospital Belfast UK"},{"name":"School of Medicine Dentistry and Biomedical Science The Wellcome\u2010Wolfson Institute for Experimental Medicine Queen's University Belfast UK"},{"name":"School of Biomedical Sciences Ulster University Coleraine UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"McCaughan","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology The Royal Group of Hospitals Belfast UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline C.","family":"Rendall","sequence":"additional","affiliation":[{"name":"Northern Ireland Regional Adult Cystic Fibrosis Centre Level 8 Belfast City Hospital Belfast UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5243-5108","authenticated-orcid":false,"given":"John E.","family":"Moore","sequence":"additional","affiliation":[{"name":"Department of Bacteriology Northern Ireland Public Health Laboratory Belfast City Hospital Belfast UK"},{"name":"School of Medicine Dentistry and Biomedical Science The Wellcome\u2010Wolfson Institute for Experimental Medicine Queen's University Belfast UK"},{"name":"School of Biomedical Sciences Ulster University Coleraine UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,9,7]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12521"},{"issue":"2","key":"e_1_2_10_3_1","first-page":"129","article-title":"Increasing burden of antimicrobial resistance in Pseudomonas aeruginosa from adult patients with cystic fibrosis (CF) in Northern Ireland: Then and now","volume":"87","author":"Gramegna A","year":"2018","journal-title":"Ulster Med J"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/crj.12787"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2018.1489721"},{"key":"e_1_2_10_6_1","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing","author":"Anon. CLSI","year":"2019"},{"key":"e_1_2_10_7_1","volume-title":"Fluoroquinolone Breakpoints for Enterobacteriaceae and Pseudomonas aeruginosa","author":"Anon. CLSI","year":"2019"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx543"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.57.11.926"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01358-0"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy165"},{"key":"e_1_2_10_12_1","volume-title":"Annex 1: Summary of Product Characteristics","author":"Anon. Quofenix (delafloxacin)"}],"container-title":["The Clinical Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcrj.13262","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/crj.13262","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/crj.13262","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/crj.13262","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T01:13:15Z","timestamp":1692666795000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/crj.13262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,7]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["10.1111\/crj.13262"],"URL":"https:\/\/doi.org\/10.1111\/crj.13262","archive":["Portico"],"relation":{},"ISSN":["1752-6981","1752-699X"],"issn-type":[{"value":"1752-6981","type":"print"},{"value":"1752-699X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,7]]},"assertion":[{"value":"2019-12-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}